Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02879695 · ClinicalTrials.gov registry record · Phase 1

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

A Phase 1 study of Recurrent B Acute Lymphoblastic Leukemia and Refractory B Acute Lymphoblastic Leukemia, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 1
Development phase
28
Enrollment target
7
Study locations

NCT02879695: Active Phase 1 study of Recurrent B Acute Lymphoblastic Leukemia and Refractory B Acute Lymphoblastic Leukemia, sponsored by National Cancer Institute (NCI).

NCT02879695 is a Phase 1 study of Recurrent B Acute Lymphoblastic Leukemia and Refractory B Acute Lymphoblastic Leukemia that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 28 participants, below the 149-participant average among 12 other Recurrent B Acute Lymphoblastic Leukemia trials with a reported enrollment target (81% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02879695, a Phase 1 study of Recurrent B Acute Lymphoblastic Leukemia and Refractory B Acute Lymphoblastic Leukemia, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
28 participants
Enrollment target
7
Study locations

Study Summary

This phase I trial studies the side effects and best dose of blinatumomab when given with nivolumab alone or nivolumab and ipilimumab in treating patients with poor-risk CD19+ precursor B-lymphoblastic leukemia that has come back after a period of improvement (relapsed) or has not responded to treatment (refractory). Immunotherapy with monoclonal antibodies, such as blinatumomab, nivolumab, and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Primary Outcome

Defined by Common Terminology Criteria for Adverse Events, version 5.0. The highest grade experienced by the participant will be reported.

Conditions Studied

Recurrent B Acute Lymphoblastic Leukemia Refractory B Acute Lymphoblastic Leukemia Recurrent Mixed Phenotype Acute Leukemia Refractory Mixed Phenotype Acute Leukemia

Interventions

  • PROCEDURE Biospecimen Collection
  • BIOLOGICAL Nivolumab
  • BIOLOGICAL Blinatumomab
  • BIOLOGICAL Ipilimumab
  • PROCEDURE Bone Marrow Aspiration and Biopsy

Study Locations (7)

Connecticut

  • Yale University - New Haven

Kentucky

  • University of Kentucky/Markey Cancer Center - Lexington

Maryland

  • Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Pennsylvania

  • University of Pittsburgh Cancer Institute (UPCI) - Pittsburgh

Utah

  • Huntsman Cancer Institute/University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2017-10-25
Est. Completion 2026-07-18
Phase Phase 1
National Cancer Institute (NCI)

3,257 total trials

What the registry record for NCT02879695 still lists

NCT02879695 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 149-participant average among 12 other Recurrent B Acute Lymphoblastic Leukemia trials with a reported enrollment target (81% lower).

The record links to 4 conditions, with Recurrent B Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT02879695 lists 7 locations in 7 states (Connecticut, Kentucky, Maryland).

Frequently Asked Questions

What is clinical trial NCT02879695 about?

NCT02879695 is a clinical study titled "Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia". This phase I trial studies the side effects and best dose of blinatumomab when given with nivolumab alone or nivolumab and ipilimumab in treating patients with poor-risk CD19+ precursor B-lymphoblastic leukemia that has come back after a period of improvement (relapsed) or has not responded to treat...

What is the current status of trial NCT02879695?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2017-10-25. Estimated completion is 2026-07-18.

What conditions does trial NCT02879695 study?

This clinical trial studies the following conditions: Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia.

What interventions are being tested in trial NCT02879695?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Nivolumab (BIOLOGICAL), Blinatumomab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), Bone Marrow Aspiration and Biopsy (PROCEDURE).

Who is sponsoring clinical trial NCT02879695?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02879695 being conducted?

This trial has 7 study locations across Connecticut, Kentucky, Maryland, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent B Acute Lymphoblastic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02879695's enrollment target sits among peer trials

28 11th of 12 higher than 2 of 12 other Recurrent B Acute Lymphoblastic Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Recurrent B Acute Lymphoblastic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02879695, the US trial registry maintained by the National Library of Medicine. NCT02879695 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.